PBMs blame insurers for high drug prices

Amy Baxter | | Health Exec | Policy & Regulations

Sky-high drug prices and healthcare costs have quickly turned into a voter issue in Washington, D.C., with politicians promising to go after pharmaceutical companies to lower prices. Pharmacy benefit managers (PBMs)—the industry middlemen that negotiate drug prices—are passing on nearly all their savings to insurance providers, according to Terry Wilcox, co-founder and executive director of advocacy organization Patients Rising. His op-ed for The Hill placed the blame of high costs squarely on insurers.

CVS Health reported it passed on 98 percent of rebates it receives from drug makers to insurers in 2018 disclosures, while Express Scripts passes on 95 percent of rebates to health plan clients and customers. These savings help subsidize premium costs for health plan members, but they also could be bolstering profits for insurers, according to Wilcox.

See the full story below:

Disclosures suggest rebates and insurers responsible for rising out-of-pocket d…

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA set to ban certain over-the-counter cold medications
FDA commissioner urges clinicians to join fight against medical misinformation
Looming fear of more IV shortages as Hurricane Rafael gains strength
Walgreens settles class-action fraud lawsuit for $100M
Boston Medical Center installs solar panels to pay patients’ electric bills
4 points crucial to the nimble regulation of GenAI

Around the web

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup